This is to inform you that pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; the Board of Directors, at their meeting held ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors met on July 23, 2025 and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26). Revenue from operations rose to ₹1,043.07 lakhs, up about 20% from ₹869.68 lakhs in Q1 FY25. Profit before tax grew to ₹204.35 lakhs (vs ₹169.17 lakhs) and profit after tax stood at ₹151.75 lakhs (standalone) / ₹153.30 lakhs (consolidated), up roughly 21% year-on-year. Basic EPS improved to ₹2.75 from ₹2.28. The Medical segment continues to be the dominant contributor, while the Telemedicine segment shows no revenue in Q1 FY26. The Board also approved the Notice of the 16th AGM. The results carry an unmodified limited review report from the new auditor, Motilal & Associates LLP, which replaced the previous statutory auditor DMKH & Co.
A clean quarter with revenue and profits both growing around 20% signals healthy operating momentum for shareholders. The change of statutory auditor mid-FY is worth monitoring, though the review report is clean and consistent with prior period figures.